Project Term
–
Project Summary
Acute myeloid leukemia remains a highly lethal disease. Menin inhibitors are an exciting new class of drugs in leukemic but are rarely curative and have significant toxicities. We seek to develop a new treatment approach for patients with leukemia by enhancing the effects of Menin inhibitors while limiting their toxicity.
Lay Abstract
Menin inhibitors (MIs) show promising activity in acute myeloid leukemia but are not curative and can cause toxicity via differentiation syndrome. This project will build on our finding that p53 activation synergizes with MIs to target KMT2A-rearranged leukemias.
We will determine how p53 activation enhances MI-driven differentiation and how MIs affect p53 signaling and protein levels. Our data will provide the rationale for a new approach to enhance the efficacy of MIs while limiting toxicity.
Program
Grant Subprogram
